IDEXX Laboratories, Inc.

IDXX · NASDAQ · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net −$457K – −$26K 14 disclosures · 5 bought / 9 sold · last Aug 21, 2026
Byron Donalds R · HOUSE · FL	$1K – $15K $876 – $13K today 1 filing · last Sep 4, 2025
Robert Bresnahan R · HOUSE · PA	−$13K – $29K −$21K – $33K today 3 filings · last May 15, 2025
April McClain Delaney D · HOUSE · MD	−$55K – $71K −$46K – $101K today 9 filings · last Jan 13, 2026
Tommy Tuberville R · SENATE · AL	−$28K – $28K −$38K – $32K today 4 filings · last Jan 22, 2024
Gilbert Ray Cisneros, Jr. D · HOUSE · CA	−$57K – $41K −$96K – $106K today 7 filings · last Oct 9, 2020
Lamar Smith R · HOUSE · TX	−$59K – $11K −$519K – $102K today 5 filings · last Jun 2, 2015
Ro Khanna D · HOUSE · CA	−$400K – $335K −$565K – $520K today 45 filings · last Aug 3, 2026
Jefferson Shreve R · HOUSE · IN	−$185K – $50K −$180K – $107K today 3 filings · last May 12, 2025

Recent transactions

Trades from Apr 1, 2025 – Aug 21, 2026

Politician	Type	Filed after	Amount
Donald Trump R · EXECUTIVE	Sell	48 days Aug 21, 2026 → Oct 8, 2026	≥$50K
Donald Trump R · EXECUTIVE	Sell	61 days Jul 23, 2026 → Sep 22, 2026	≥$15K
Donald Trump R · EXECUTIVE	Sell	67 days Jul 17, 2026 → Sep 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	76 days Jul 8, 2026 → Sep 22, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	32 days Aug 3, 2026 → Sep 4, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	60 days Jun 23, 2026 → Aug 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	67 days Jun 16, 2026 → Aug 22, 2026	≥$15K
Donald Trump R · EXECUTIVE	Sell	71 days Jun 12, 2026 → Aug 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	80 days Jun 3, 2026 → Aug 22, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	6 days Jun 30, 2026 → Jul 6, 2026	≥$1K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

1,329

13F shares

75.1M

Total invested

$39.4B

Ownership

93.7%

New positions

119

Closed positions

128

Increased positions

593

Reduced positions

510

Put/Call ratio

0.48

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	8.2M	$4.3B	−2.34%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	5.2M	$2.7B	−0.58%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	3.9M	$2.1B	−0.37%
STATE STREET CORP	9/22/2026	3.7M	$2.0B	+2.03%
INVESCO LTD.	8/14/2026	3.6M	$1.9B	+116.11%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	2.6M	$1.3B	−3.69%
BAMCO INC /NY/	8/14/2026	2M	$1.0B	+21.02%
MORGAN STANLEY	8/13/2026	1.4M	$713.9M	+3.05%
BANK OF NEW YORK MELLON CORP	8/6/2026	1.2M	$628.2M	−20.68%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	8/13/2026	1.1M	$561.8M	+27.21%
FUNDSMITH LLP	8/14/2026	1M	$536.9M	−30.42%
BLAIR WILLIAM & CO/IL	8/11/2026	918.6K	$483.6M	−2.94%
NORTHERN TRUST CORP	8/13/2026	918.1K	$483.3M	+0.68%
UBS ASSET MANAGEMENT AMERICAS INC	8/13/2026	911.5K	$479.8M	+4.55%
FMR LLC	8/13/2026	822.6K	$433.1M	+190.71%
AMERICAN CENTURY COMPANIES INC	8/12/2026	808.4K	$425.6M	+34.74%
CAPITAL RESEARCH GLOBAL INVESTORS	8/12/2026	789.1K	$415.5M	+0.99%
JPMORGAN CHASE & CO	8/12/2026	755.8K	$405.1M	−3.09%
PRINCIPAL FINANCIAL GROUP INC	8/4/2026	743.2K	$391.3M	−15.65%
GOLDMAN SACHS GROUP INC	8/14/2026	738.7K	$388.9M	+3.04%
WELLINGTON MANAGEMENT GROUP LLP	8/14/2026	726.7K	$382.6M	−1.19%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	650.4K	$342.4M	—
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	650.4K	$342.4M	+6.59%
LEGAL & GENERAL GROUP PLC	8/14/2026	617.2K	$324.9M	−5.16%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	608.9K	$320.6M	+6.20%

Insider transactions

Insider	Type	Transacted	Price	Date
Fennell George	M-EXEMPT	639	—	Jun 1
Fennell George	M-EXEMPT	639	—	Jun 1
Fennell George	F-INKIND	284	$566.79	Jun 1
Vandebroek Sophie V.	A-AWARD	234	—	May 12
Vandebroek Sophie V.	A-AWARD	525	$533.92	May 12
Samad Sam	A-AWARD	525	$533.92	May 12
Samad Sam	A-AWARD	234	—	May 12
Peacock Karen	A-AWARD	525	$533.92	May 12
Peacock Karen	A-AWARD	234	—	May 12
Kingsley Lawrence D	A-AWARD	234	—	May 12

Analyst consensus

Buy23 analysts

Bearish · 1 · Hold · 9 · Bullish · 13

Earnings history

	EPS	Estimate
Q3 2024	$2.80	$2.68	Beat
Q4 2024	$2.62	$2.39	Beat
Q1 2025	$2.96	$2.85	Beat
Q2 2025	$3.63	$3.28	Beat
Q3 2025	$3.40	$3.14	Beat
Q4 2025	$3.08	$2.93	Beat
Q1 2026	$3.47	$3.41	Beat
Q2 2026	$4.27	$3.94	Beat

Peers

Company overview

IPO dateJun 21, 1991

CEOMichael Erickson

Employees11,000

SectorHealthcare

IndustryMedical - Diagnostics & Research

CountryUS

ExchangeNASDAQ Global Select

Websitewww.idexx.com

IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.